New eye implant aims to stop vision loss from diabetes

NCT ID NCT06003751

Completed Disease control Sponsor: Perfuse Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested a new eye implant called PER-001 in 27 people with diabetic retinopathy, a diabetes complication that can damage vision. The implant is placed inside the eye and releases medication over time. The main goal was to check safety and how well people tolerate it, looking at vision changes and eye pressure. The trial is now complete, but results are not yet available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PER-001 intravitreal implant
What this could lead to: If successful, this could lead to a new treatment option for diabetic retinopathy that helps preserve vision.
What could go wrong: This is a small, early-phase trial focused on safety, not effectiveness. The implant may not improve vision or could cause side effects like eye pressure changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETIC RETINOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetic retinopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETIC RETINOPATHY

Contacts and locations

Locations

Perfuse Therapeutics, Inc

San Francisco, California, 94158, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.